HIHideharu Ideguchi

Hideharu Ideguchi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hideharu Ideguchi has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Four-meter gait speed predicts daily physical activity in patients with chronic respiratory diseases

    by Chieko Yoshida, Hidenori Ichiyasu, Hideharu Ideguchi, Susumu Hirosako, Aiko Masunaga, Keisuke Kojima, Sho Saeki, Kazuhiko Fujii, Takuro Sakagami, Hirotsugu Kohrogi


  • Open Access

    Clinical effects of direct hemoperfusion using a polymyxin B-immobilized fiber column in clinically amyopathic dermatomyositis-associated rapidly progressive interstitial pneumonias

    by Hiroko Okabayashi, Hidenori Ichiyasu, Sayuri Hirooka, Kimitaka Akaike, Keisuke Kojima, Takayuki Jodai, Yasumiko Sakamoto, Hideharu Ideguchi, Shohei Hamada, Chieko Yoshida, et al.

    Rapidly progressive interstitial pneumonias (RPIPs) associated with clinically amyopathic dermatomyositis (CADM) are highly resistant to therapy and have a poor prognosis. Multimodal therapies, including direct hemoperfusion using a polymyxin B-immobilized fiber column (PMX-DHP), have a protective effect on RPIPs. We evaluated the effects of PMX-DHP on CADM-associated RPIPs. We retrospectively enrolled 14 patients with CADM-associated RPIPs and acute respiratory failure treated with PMX-DHP, corticosteroids, and immunosuppressive agents. Clinical manifestations were compared between survivors and non-survivors at 90 days after PMX-DHP. The survival rate at 90 days after PMX-DHP was 35.7% (5/14). Before PMX-DHP, the survivor group exhibited a significantly higher PaO2/FiO2 (P/F) ratio and serum surfactant protein-D (SP-D) levels and significantly lower lactate dehydrogenase (LDH) and ferritin levels than the non-survivor group. Platelet counts were significantly decreased after PMX-DHP therapy in both groups, but remained higher in the survivor group than the non-survivor group over the course of treatment. Anti-melanoma differentiation-associated gene 5 (MDA-5) antibody positive patients demonstrated a poor 90-day survival rate, lower platelet counts and P/F ratio, and higher LDH levels than anti-MDA-5 antibody negative patients. CADM-associated RPIPs with anti-MDA-5 antibody is associated with a very poor prognosis. A higher P/F ratio and SP-D level, lower LDH and ferritin levels, higher platelet counts, and anti-MDA-5 antibody negativity are important prognostic markers in patients with CADM-associated RPIPs treated with PMX-DHP.